Health Catalyst (HCAT) to Release Quarterly Earnings on Thursday

Key Points

• Health Catalyst (HCAT) is set to release its Q2 2025 earnings after market close on August 7th, with expectations of $0.05 earnings per share and $80.59 million in revenue.
• The company's stock price opened at $3.68, with a market cap of $256.13 million and significant fluctuations over the past year, ranging from $3.49 to $9.24.
• Analysts have a mixed outlook on the stock, with a consensus rating of "Moderate Buy" and an average price target of $8.00, amid varying price target adjustments from several firms.

Health Catalyst (NASDAQ:HCAT - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Health Catalyst to post earnings of $0.05 per share and revenue of $80.59 million for the quarter.

Health Catalyst Stock Down 3.6%

Shares of HCAT traded down $0.13 during trading hours on Friday, reaching $3.52. The stock had a trading volume of 718,722 shares, compared to its average volume of 672,296. Health Catalyst has a 12 month low of $3.48 and a 12 month high of $9.24. The firm has a 50-day simple moving average of $3.86 and a 200 day simple moving average of $4.35. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $245.00 million, a price-to-earnings ratio of -3.06 and a beta of 1.51.

Wall Street Analysts Forecast Growth

HCAT has been the topic of several recent analyst reports. Canaccord Genuity Group dropped their price objective on Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus raised their price objective on Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a research note on Thursday, May 8th. Evercore ISI dropped their price objective on Health Catalyst from $5.00 to $4.00 and set an "in-line" rating on the stock in a research note on Wednesday, July 9th. Citigroup dropped their price objective on Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a research note on Friday, April 25th. Finally, BTIG Research cut Health Catalyst from a "buy" rating to a "neutral" rating in a research note on Tuesday, June 17th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Institutional Investors Weigh In On Health Catalyst

Large investors have recently added to or reduced their stakes in the company. Focus Partners Wealth purchased a new stake in Health Catalyst in the 1st quarter worth about $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company's stock valued at $163,000 after buying an additional 2,624 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in Health Catalyst by 816.8% during the 1st quarter. AQR Capital Management LLC now owns 168,344 shares of the company's stock valued at $763,000 after buying an additional 149,981 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.